Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Completes RayThera Acquisition | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Biogen Completes RayThera Acquisition

The acquisition and the entering of a lead program into Phase I development both happened on schedule.

Author Image

By: Patrick Lavery

Content Marketing Editor

Why This Matters: Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Biogen announced the completion of its acquisition of RayThera, a deal previously reported to be worth up to $1 billion. RayThera, a privately held biotechnology company, focused on discovery and development of small molecule therapies in immunology.

Considering RayThera’s background, Biogen views the acquisition as a boost to its immunology portfolio. Multiple RayThera assets, Biogen says, show potential to treat immune-mediated conditions over a range of indications.

RayThera Acquisition Background

When Biogen announced the pending acquisition, in June, RayThera’s lead program was about to enter Phase I development. That happened early in the third quarter of 2026—in July, as expected.

The acquisition itself also had an anticipated closing date of Q3 2026. That has now happened as well.

Biogen Looks Forward

Biogen Executive Vice President and Head of Development Priya Singhal, MD, said this positions the company’s pipeline for long-term growth.

“We are excited about the potential of these immunology assets,” Singhal said. “With the lead program in Phase I, this highlights strong execution on our open innovation model in sourcing external opportunities. [It] reflects our continued investment in immunology as a strategic growth area.”

Biogen will lead development, manufacturing, and global commercialization of all acquired RayThera assets moving forward.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics